Table 1 Patient characteristics
|  | Total Cohort n = 159 |
|---|---|
Age at HL diagnosis (years) | 27 (20 – 36) |
Female | 100 (62.9%) |
Race | |
 White | 151 (95.0%) |
 Black | 4 (2.5%) |
 Other | 4 (2.5%) |
Radiation dose to chest (Gray) | 37.2 (36 – 42) |
 Mantle radiation or cumulative dose ≥ 35 Gy | 120 (88.9%) |
Chemotherapy | 108 (68.4%) |
 Anthracycline | 84 (57.1%) |
 Anthracycline dose (mg/m2) | 300 (200–300) |
 Cumulative anthracycline dose ≥ 250 mg/m2 | 40 (64.5%) |
Decade of treatment | |
 1960–69 | 4 (2.5%) |
 1970–79 | 25 (15.7%) |
 1980–89 | 49 (30.8%) |
 1990–99 | 47 (29.6%) |
 2000–09 | 27 (17.0%) |
 2010–20 | 7 (4.4%) |
Age at time of functional study (years) | 48 (42 – 56) |
Years between HL diagnosis and functional study | 20 (11 – 28) |
Hypertension | 52 (32.7%) |
Dyslipidemia | 54 (34.0%) |
Diabetes | 4 (2.5%) |
Family history of premature CAD | 35 (22.0%) |
Former or current tobacco use | 27 (17.0%) |
BMI ≥ 30 kg/m2 | 31 (19.5%) |
Morise score | 6.4 (2.6) |
Pre-test probability of CAD by Morise score | |
 Low (0–8 points) | 124 (78.0%) |
 Intermediate (9–15 points) | 35 (22.0%) |
 High (16–24 points) | 0 (0.0%) |
On aspirin therapy | 31 (19.5%) |
On statin therapy | 35 (22.0%) |